Idaho to receive part of $300 million settlement with drugmaker Indivior
Pixabay
BOISE, Idaho (KIFI) - Attorney General Lawrence Wasden announced Idaho and other states have reached an agreement with Indivior plc and Indivior Inc. to settle allegations that the company falsely and aggressively marketed and promoted the drug Suboxone, resulting in improper expenditures of state Medicaid funds.
Suboxone is a drug approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms while they undergo treatment. Suboxone and its active ingredient, buprenorphine, are powerful and addictive opioids.
Indivior will pay $300 million to resolve various civil fraud allegations impacting Medicaid and other government healthcare programs. Idaho’s share is $95,019 and will be paid out over seven years. Approximately $38,000 will go to the state’s Medicaid program and $57,000 to the state’s general fund.